Structure Therapeutics price target lowered to $113 from $120 at Citizens

Citizens analyst Jonathan Wolleben lowered the firm’s price target on Structure Therapeutics (GPCR) to $113 from $120 and keeps an Outperform rating on the shares. Structure Therapeutics is entering a catalyst-rich year highlighted by multiple aleniglipron updates, including upcoming 44-week ACCESS II data and an end-of-Phase 2 FDA meeting to finalize Phase 3 design, following Phase 2b results showing 11%-15% placebo-adjusted weight loss at 36 weeks with improved tolerability at a 2.5 mg starting dose, the analyst tells investors in a research note. With strong early uptake of oral GLP-1s reinforcing demand for effective oral therapies, Structure appears well-positioned in obesity with a potential best-in-class oral candidate and an expanding metabolic pipeline, the firm says.